Lpath wins US patent for anti-S1P antibody to treat ocular conditions
The patent includes the use of monoclonal antibodies, including the company’s therapeutic antibody iSONEP that binds sphingosine-1-phosphate (S1P). Lpath vice president, founder, and an inventor of the granted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.